Novel Treatment to Prevent Graft-Versus-Host-Disease

Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants.

Stem cell transplants can be used to treat patients who have certain types of cancer, such as leukemia or lymphoma. Many patients who have stem cell transplants receive an allogeneic transplant - stem cells donated by another person.

One risk associated with allogeneic stem cell transplants is graft-versus-host-disease (GVHD) during which the donated immune cells fail to recognize the patient's own tissues and organs. The symptoms of GVHD vary and can be life-threatening. Common symptoms include rash, nausea and vomiting, diarrhea, and occasionally jaundice and liver failure.

Post-Bone Marrow Transplant, Biomarker Detects Graft-Versus-Host-Disease in Cancer Patients
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia,

‘A novel treatment can effectively inhibit the development of graft-versus-host-disease (GVHD) in mice and maintain the infection- and tumor-fighting capabilities of the immune system.’

In order to reduce the risk of GVHD, physicians try to match the recipient and donor tissue types as close as possible and prophylactic medicine is given throughout the transplant process. However, patients may still develop GVHD.

The medications used to prevent GVHD are not very selective and suppress the activity of many different immune cell types; good and bad. As a result, GVHD prevention can increase the risk of serious infections and also inhibit the ability of donor immune cells from fighting against residual leukemia or lymphoma cells.

In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.

Blood Cancer Drug 'Ibrutinib' Shows Promise For Treating Graft Versus Host Disease
Anticancer drug Ibrutinib shows hope in the treatment of graft versus host disease after stem cell transplantation.

"It is known that Aurora kinase A and JAK2 pathway activation contributes to GVHD. However, drugs that inhibit either protein alone do not completely prevent GVHD," said Betts. "We hypothesized that co-treatment with drugs that target both Aurora kinase A and JAK2 could prevent GVHD better than either drug alone."

The researchers discovered that combined inhibition of Aurora kinase A and JAK2 promotes the differentiation of potent regulatory T cells, specialized immune cells that prevent GVHD. Aurora kinase A and JAK2 also significantly reduced GVHD in mice and allowed for the development of anti-cancer immune cells. This was best demonstrated by a drug developed at Moffitt that inhibits both Aurora kinase A and JAK2 simultaneously, eliminating the need to use two different medications.

Cord Blood Transplant Therapy Approved by FDA
The US FDA has now approved the first cord-blood transplant therapy- HEMACORD.

"This novel prevention strategy warrants further investigation because of its potential to reduce the risk of GVHD and possibly be more effective and selective than commonly used GVHD treatments currently available today," added Betts.

Source-Eurekalert

New Test to Predict Success of Stem Cell Transplants in Leukemia
A new test could reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT).